StreetAlpha.app
Home › Stocks › CLYM

Climb Bio, Inc. (CLYM)

Healthcare
$9.19
▼ −0.97%
LAST CLOSE · NOV 20

Climb Bio develops antibody medicines for immune system diseases, including rare kidney and blood disorders. It last closed at $9.19 on Nov 20, down 0.97% on the day. The next earnings report for CLYM is expected around Thu, Mar 4, 2027. For the quarter ended Sep 2026, CLYM reported EPS of -$0.18. Over its last 8 reports the stock moved an average of 4.1% the session after earnings. Over the last 12 months CLYM insiders bought $780K of stock on the open market and sold $2.7M, according to SEC Form 4 filings.

AI Auto Pilots
Is CLYM in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CLYM.

Key Stats

Last 12 months
Results
Net income
−$59.3M
EPS (diluted)
−$0.81
Free cash flow
−$53.6M
Valuation
Market cap
$539.8M
58.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$39.7M
At Sep 30
Shareholder equity
$228.1M
Shares outstanding
58.7M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$47.5M−$47.5MFY2021FY2022: −$45.2M−$45.2MFY2022FY2023: −$35.1M−$35.1MFY2023FY2024: −$73.9M−$73.9MFY2024FY2025: −$59.9M−$59.9MFY2025

From CLYM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 4
Estimated date · Time not announced
Reported EPS
-$0.18
Quarter ended Sep 2026
Year ago EPS
-$0.19
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.04Dec '24Mar 2025: -$0.31Mar '25Jun 2025: -$0.13Jun '25Sep 2025: -$0.19Sep '25Dec 2025: -$0.25Dec '25Mar 2026: -$0.20Mar '26Jun 2026: -$0.18Jun '26Sep 2026: -$0.18Sep '26Latest -$0.18
Revenue by quarter
Not enough quarters on file yet.
How CLYM moved after its last 8 reports
Average move the session after a report ±4.1%
Nov 5, 2026Time not announced−4.9%
Aug 6, 2026Time not announced+12.3%
May 7, 2026Time not announced−2.5%
Mar 5, 2026Time not announced+1.5%
Nov 6, 2025Time not announced+1.6%
Aug 12, 2025Time not announced−2.4%
May 14, 2025Time not announced−7.9%
Mar 25, 2025After the close0.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CLYMStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CLYM
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CLYM

Technical Analysis

CLYM · as of the Nov 20 close · updated each morning
Turning down

The stock is 9% below its 20 day and 20% below its 50 day average. It is 17% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the Pivot at $9.16, and the nearest resistance the Pivot R1 at $9.43.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityNormal, 9.6%/day
Key levels
$18.3352 week high+99.5%
$12.60100 day average+37.1%
$11.0150 day average+19.8%
$10.79200 day average+17.4%
$10.55Swing high (Oct 29)+14.8%
$10.0420 day average+9.2%
$9.43Pivot R1+2.6%
$9.19Last close
$9.16Pivot−0.3%
$8.93Pivot S1−2.8%
$8.70Swing low (Oct 26)−5.3%
$1.6452 week low−82.2%
Indicators
RSI (14)40.54Middle of its rangeNeutral
MACD-0.37Below its signal lineBearish
Stochastic19.5Near the bottom of its rangeOversold
ADX (14)26.1Trending down
Williams %R-82.2Oversold below −80, overbought above −20Oversold
CCI (20)-93.2Oversold below −100, overbought above 100Neutral
Rate of change−10.7%Change over 10 sessionsBearish
ATR (14)$0.89Typical daily range, 9.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CLYM

What happened before

See how CLYM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CLYM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CLYM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CLYMHow many large options trades hit CLYM, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CLYM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲89 buying vs 35 selling
  • ▲Held by funds +15.2 pts
  • ▲Funds holding +19
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding128109+17.4%
In funds' top 10110.0%
Held by funds111.1%95.9%+15.2 pts
New / increased31 / 5852 / 32+6.0%
Reduced / sold out22 / 1318 / 22−12.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CLYM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CLYM Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$780K2 buys · 2 insiders
Sold$2.7M4 sales · 2 insiders
100% of the selling was under pre-arranged trading plans.
Cluster buy: 2 insiders bought $780K between Dec 11 and Jan 5.
2025-12 bought $755K2026-01 bought $25K2026-02 sold $879K2026-06 sold $407K2026-09 sold $1.4MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 15Stephen Basil ThomasDirectorSale plan100,000$13.67$1.4M
Jun 29Aoife BrennanPresident and CEOSale plan30,902$13.17$407K
Feb 26Stephen Basil ThomasDirectorSale plan50,000$7.00$350K
Feb 13Stephen Basil ThomasDirectorSale plan100,000$5.29$529K
Jan 5RA Capital Healthcare Fund LPDirectorBuy7,111$3.50$25K
Dec 12, 2025Peter KolchinskyDirectorBuy314,561$2.40$755K
Every insider buy and sale for CLYM over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CLYM insider trades →

From SEC Form 4 filings by CLYM's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CLYM is in one of them and how their past CLYM trades turned out.

CLYM in the AI portfolios
Loading…

CLYM News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CLYM in an article yet. Here's the latest on the wider market.

CLYM in the news

About Climb Bio

Climb Bio is a biotechnology company based in Wellesley Hills, Massachusetts. It is developing antibody medicines for diseases in which the immune system attacks the body. Its lead candidate, budoprutug, is designed to deplete a type of B cell and is being tested in patients with membranous nephropathy, a rare kidney disease, as well as immune thrombocytopenia and lupus. A second candidate, CLYM116, targets a protein linked to IgA nephropathy, a kidney condition. Its candidates are still in clinical trials and are not yet sold.

Headquarters
Wellesley Hills, MA